AIM ImmunoTech has launched a strategic initiative to develop Ampligen as a vaccine adjuvant targeting avian influenza, marking a significant advancement in their antiviral development pipeline. The company has partnered with Amarex Clinical Research to manage the Investigational New Drug (IND) application process for this promising combination therapy approach.
The planned clinical study will investigate the combined use of Ampligen with AstraZeneca's FluMist, a widely-used nasal spray vaccine for seasonal influenza prevention. This research builds upon compelling preliminary findings from earlier studies conducted at the University of Alabama-Birmingham.
Promising Previous Research Results
The initial research demonstrated remarkable outcomes when Ampligen was administered intranasally following FluMist vaccination. Key findings included:
- Greater than four-fold increase in immune response to seasonal influenza variants
- Development of cross-reactive secretory Immunoglobulin A against multiple highly pathogenic avian influenza strains:
- H5N1
- H7N9
- H7N3
Strategic Development Approach
To advance this promising research, AIM ImmunoTech is actively pursuing collaborative grants from both government agencies and industry partners to support the study's funding requirements. This approach reflects the company's commitment to developing innovative solutions while managing research costs effectively.
The potential implications of this research are particularly significant given the ongoing global concern about avian influenza outbreaks and the need for more effective cross-protective vaccines. The combination therapy approach could represent a meaningful advance in influenza prevention strategies, particularly against highly pathogenic avian strains.
Clinical Development Plans
The upcoming clinical trial will expand upon the previous research, focusing on validating and extending the earlier findings. The intranasal delivery method represents a practical and potentially more effective approach to vaccination, particularly for respiratory viruses.
The collaboration between AIM ImmunoTech and Amarex Clinical Research brings together complementary expertise in drug development and clinical trial management, positioning the project for efficient advancement through the regulatory process.
